Details for Patent: 9,345,692
✉ Email this page to a colleague
Title: | Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-s- piro[4.5]decan-2-one and treatment methods using the same |
Abstract: | Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. |
Inventor(s): | Qiu; Zhihui (Bridgewater, NJ), Reyderman; Larisa (Watchung, NJ) |
Assignee: | OPKO Health, Inc. (Miami, FL) |
Filing Date: | Mar 19, 2013 |
Application Number: | 13/847,242 |
Claims: | 1. A method of treating nausea and/or emesis in a mammal comprising administering to the mammal a pharmaceutical formulation comprising a crystalline tosylate salt of (5S,8S)-8-[{(1R)-1-(3,5-bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one, and a pharmaceutically acceptable excipient, and wherein said nausea and/or emesis arises from chemotherapy, radiation therapy, motion sickness, morning sickness, or inner ear disturbances and infections, or wherein said nausea and/or emesis arises during a post-operative recovery period. 2. The method according to claim 1 wherein the pharmaceutically acceptable excipient is selected from at least one of the group consisting of lactose, microcrystalline cellulose, croscarmellose sodium, pregelantinized starch, and magnesium stearate. 3. The method of claim 1 wherein the formulation is a granular formulation. 4. The method of claim 1 wherein the amount of active ingredient ranges from 5-200 mg per dosage form. 5. The method of claim 1 wherein the dosage form contains 200 mg of the crystalline tosylate salt (5S,8S)-8-[{(1R)-I-(3,5-Bis-(trifluoromethyl)pheny]-ethoxy}-methyl]-8-phe- nyl-1,7-diazaspiro[4.5]decan-2-one. |